CMO Letter to Reduce Inappropriate Antibiotic Prescribing Winter 2019/2020
NCT ID: NCT04051281
Last Updated: 2020-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2963 participants
INTERVENTIONAL
2019-08-31
2020-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There will be three intervention samples:
1. practices whose prescribing in the past year was under the new target of 0.965 items per STAR-PU but who would exceed the target if they had a 5% increase in prescribing; trial compares prescribing of practices whose GPs receive a letter informing them that their practice's prescribing is just under the new target to that of practices that are not sent a letter
2. Practices whose prescribing in the past year was above the new target but who not in the top 20% of prescribers; trial compares prescribing of practices whose GPs receive a letter informing them that their practice's prescribing exceeds the new target to practices who get a letter that includes a graph showing their prescribing relative to the target and to practices that are not sent a letter
3. Practices that are currently in the top 20% of prescribers; trial compares effect on prescribing of a feedback letter with a social norms message (current standard practice for this group) to a letter informing GPs that their practice's prescribing exceeds the new target and to a letter with a social norms message, that includes a specific example of a case of patient harm caused by antimicrobial resistance.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CMO Letter to Reduce Unnecessary Antibiotic Prescribing March 2018
NCT03582072
CMO Letter to Reduce Unnecessary Antibiotic Prescribing and Broad Spectrum Prescribing Winter 2018-9
NCT03862794
Interventions on Non-prescription Dispensing of Antibiotics in Community Pharmacies
NCT06521892
Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care
NCT01773824
A Trial to De-prescribe Inappropriate Medications in the Community Dwelling Elderly
NCT02053194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Trial 1 Targeting practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing
* Control: No letter
* Intervention: Letter informing them that their practice's prescribing is just under the new target (Letter A) Trial hypothesis: Sending a letter to GPs whose practices are just under the new prescribing target will reduce antibiotic prescribing
Trial 2 Targeting practices whose prescribing in the past year was above the new target but who not in the top 20% of prescribers
* Control: No letter
* Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)
* Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2) Hypotheses: (i) Sending a letter to GPs whose practices missed the new prescribing target will reduce their prescribing; (ii) A letter with a graph will be more effective than a letter without a graph.
Trial 3 Targeting practices that are currently in the top 20% of prescribers
* Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1)
* Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter C2)
* Intervention 2: Social norms message, that they are in the top 20%, with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)
Hypotheses: (i) A letter with a social norms message and a specific example of a case where a patient came to harm will be more effective than a feedback letter without a specific example; (ii) A letter telling GPs that they missed the prescribing target will be no less effective than a letter with social norms feedback
For each letter, there will be two versions, one for practices whose prescribing has increased by \> 5% in the previous year, informing them of that their prescribing has increased since the previous year, and one for practices whose prescribing has not been increasing.
The letters will signpost GPs to resources to help address patient demand for inappropriate antibiotic prescribing, recognising that many GPs feel that patients expect antibiotics and that GPs may find it difficult to have the necessary patient conversations, especially within a short consultation. As with previous letters, these letters will advise GPs of actions that they can take to reduce inappropriate prescribing, supporting them to have conversations with patients, and there will be TARGET leaflets enclosed.
Power calculation All trials are powered to detect a 2% reduction in prescribing at a significance level of 0.05 with a power of 80%.
Statistical analysis plan In order to test our hypotheses, the investigators will use a fixed effects panel regression model, with time trends accounting for seasonal effects, to estimate the effect of treatment status on prescribing. The investigators will also run ANCOVAs for each month separately and one covering the whole six months of the trial. Analysis will control for baseline prescribing rates and for whether practices got the version of the letter saying that their prescribing has been increasing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Just under target control
Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing; no letter sent.
No interventions assigned to this group
Just under target letter
Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing: receive a letter informing of this.
Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter
Letter
Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Over target control
Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; no letter sent
* Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)
* Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2)
No interventions assigned to this group
Over target letter
Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target (Letter B1)
Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter
Letter
Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Over target letter with bar chart
Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target, including a bar chart showing their prescribing compared to the target (Letter B1)
Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter
Letter
Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Top 20% feedback letter control
Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on--standard practice--(Letter C1)
Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter
Letter
Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Top 20% above target letter
Targeting practices that are currently in the top 20% of prescribers; letters informing them that their prescribing exceeds the new target (Letter C2)
Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter.
Letter
Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Top 20% feedback letter with specific example of patient harm
Targeting practices that are currently in the top 20% of prescribers
• Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1) Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)
Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter.
Letter
Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Letter
Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Public Health England
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Public Health England
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMO Letter 2019/20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.